Evidence map›Paper›PMID 38482150›Full record

ArticleThe Lancet regional health. Southeast Asia2024

Characteristics and clinical outcomes of patients with pre-delta, delta and omicron SARS-CoV-2 infection in Indonesia (2020-2023): a multicentre prospective cohort study.

Anis Karuniawati, Ayodhia Pitaloka Pasaribu, Gilbert Lazarus, Vera Irawany, Dwi Utomo Nusantara, Robert Sinto, Suwarti, Maulana Jamil Nasution, Ferawati, Muhammad Riza Lubis and 24 more

Abstract read
In one paragraph

Article in The Lancet regional health. Southeast Asia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. In-hospital mortality among children and adults hospitalized with COVID-19 in Africa across pre-delta, delta, and omicron SARS-CoV-2 waves.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
    Article
  8. Article
  9. Review
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Anis KaruniawatiDepartment of Microbiology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.
Ayodhia Pitaloka PasaribuDepartment of Paediatrics, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Gilbert LazarusOxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Vera IrawanyFatmawati General Hospital, Jakarta, Indonesia.
Dwi Utomo NusantaraPasar Minggu Hospital, Jakarta, Indonesia.
Robert SintoDivision of Tropical and Infectious Diseases, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
SuwartiOxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Maulana Jamil NasutionYayasan Penguatan Kesehatan Masyarakat Tridarma (YPKMT/THEMP Foundation), Medan, Indonesia.
FerawatiFatmawati General Hospital, Jakarta, Indonesia.
Muhammad Riza LubisYayasan Penguatan Kesehatan Masyarakat Tridarma (YPKMT/THEMP Foundation), Medan, Indonesia.
Eka NurfitriFatmawati General Hospital, Jakarta, Indonesia.
Mutiara MutiaraMurni Teguh Memorial Hospital, Medan, Indonesia.
Hasanul ArifinBunda Thamrin Hospital, Medan, Indonesia.
Hely HelyBunda Thamrin Hospital, Medan, Indonesia.
Pramaisshela Arinda D PutriPasar Minggu Hospital, Jakarta, Indonesia.
Ariel PradiptaGenomik Solidaritas Indonesia Lab, Jakarta, Indonesia.
Anindya Pradipta SusantoGenomik Solidaritas Indonesia Lab, Jakarta, Indonesia.
Meutia Ayuputeri KumaheriGenomik Solidaritas Indonesia Lab, Jakarta, Indonesia.
BonifaciusKaritas Hospital, Sumba Barat Daya, East Nusa Tenggara, Indonesia.
Yacobus Da CostaPratama Reda Bolo Hospital, Sumba Barat Daya, East Nusa Tenggara, Indonesia.
Claus BoghSumba Foundation, Sumba Barat, East Nusa Tenggara, Indonesia.
Dodi SafariEijkman Molecular Biology Research Center, National Research and Innovation Agency, Jakarta, Indonesia.
Kartini LidiaFaculty of Medicine, Universitas Nusa Cendana, Kupang, Indonesia.
Hermi Indita MalewaProf. Dr. W.Z. Johannes Hospital, Kupang, Indonesia.
Nunung NuraeniOxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Sabighoh ZanjabilaOxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Mutia RahardjaniOxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Fitri Agustia DewiOxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Fitria WulandariOxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Decy SubektiOxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Henry SurendraOxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
J Kevin BairdOxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Anuraj H ShankarOxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Raph L HamersOxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Limited data exist from southeast Asia on the impact of SARS-CoV-2 variants and inactivated vaccines on disease severity and death among patients hospitalised with COVID-19. Methods: A multicentre hospital-based prospective cohort was enrolled from September 2020 through January 2023, spanning pre-delta, delta, and omicron periods. The participant hospitals were conveniently sampled based on existing collaborations, site willingness and available study resources, and included six urban and two rural general hospitals from East Nusa Tenggara, Jakarta, and North Sumatra provinces. Factors associated with severe disease and day-28 mortality were examined using logistic and Cox regression. Findings: Among 822 participants, the age-adjusted percentage of severe disease was 26.8% (95% CI 22.7-30.9) for pre-delta, 50.1% (44.0-56.2) for delta, and 15.2% (9.7-20.7) for omicron. The odds of severe disease were 64% (18-84%) lower for omicron than delta (p < 0.001). One or more vaccine doses reduced the odds of severe disease by 89% (65-97%) for delta and 98% (91-100%) for omicron. Age-adjusted mortality was 11.9% (8.8-15.0) for pre-delta, 24.4% (18.8-29.9) for delta and 9.6% (5.2-14.0) for omicron. The day-28 cumulative incidence of death was lower for omicron (9.2% [5.6-13.9%]) than delta (28.6% [22.0-35.5%]) (p < 0.001). Severe disease on admission was the predominant prognostic factor for death (aHR34.0 [16.6-69.9] vs mild-or-moderate; p < 0.001). After controlling for disease severity on admission as an intermediate, the risk of death was 48% (32-60%) lower for omicron than delta (p < 0.001); and 51% (38-61%; p < 0.001) lower for vaccinated participants than unvaccinated participants overall, and 56% (37-69%; p < 0.001) for omicron, 46% (-5 to 73%; p = 0.070) for pre-delta (not estimable for delta). Interpretation: Infections by omicron variant resulted in less severe and fatal outcomes than delta in hospitalised patients in Indonesia. However, older, and unvaccinated individuals remained at greater risk of adverse outcomes. Funding: University of Oxford and Wellcome Trust.

Indexed as

COVID-19Disease severityInactivated vaccineIndonesiaMortalityProspective studySARS-CoV-2 variants of concern

Identifiers

PMID38482150
PMCPMC10934308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.